TokenPost·
Wave Life Sciences Sets Oct. 27, 2026 Q3 Review, Expects WVE-006 Data in Q4 2026
$490.6M
cash on hand
Cash, cash equivalents and marketable securities totaled $490.6 million at June 30, with the balance expected to fund operations into the third quarter of 2028.